https://www.selleckchem.com/pr....oducts/Puromycin-2HC
For 18/29, DRV/r was maintained after VF, and controlled viremia was restored after modification of DRV-associated antiretroviral molecules or increased DRV dose. Finally, only 6/29 patients selected new DRV RAMs after DRV/r initiation. All of these experienced previous VFs while on other PIs. These results highlight the efficacy and robustness of DRV/r, as the emergence of DRV RAMs appeared in 0.4% of patients receiving a DRV/r-based regimen in our large cohort. These results highlight the efficacy and robustness of DRV/r, a